Prediction of pre-eclampsia-related complications in women with suspected or confirmed pre-eclampsia: development and internal validation of clinical prediction model

Ultrasound Obstet Gynecol. 2021 Nov;58(5):698-704. doi: 10.1002/uog.23142. Epub 2021 Oct 6.

Abstract

Objective: A model that can predict reliably the risk of pre-eclampsia (PE)-related pregnancy complications does not exist. The aim of this study was to develop and validate internally a clinical prediction model to predict the risk of a composite outcome of PE-related maternal and fetal complications within 7, 14 and 30 days of testing in women with suspected or confirmed PE.

Methods: The data for this study were derived from a prospective, multicenter, observational cohort study on women with a singleton pregnancy and suspected or confirmed PE at 20 to < 37 weeks' gestation. For the development of the prediction model, the possible contribution of clinical and standard laboratory variables, as well as the biomarkers soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF) and their ratio, in the prediction of a composite outcome of PE-related complications, consisting of maternal and fetal adverse events within 7, 14 and 30 days, was explored using multivariable competing-risks regression analysis. The discriminative ability of the model was assessed using the concordance (c-) statistic. A bootstrap validation procedure with 500 replications was used to correct the estimate of the prediction model performance for optimism and to compute a shrinkage factor for the regression coefficients to correct for overfitting.

Results: Among 384 women with suspected or confirmed PE, 96 (25%) had an adverse PE-related outcome at any time after hospital admission. Important predictors of adverse PE-related outcome included sFlt-1/PlGF ratio, gestational age at the time of biomarker measurement and protein-to-creatinine ratio as continuous variables. The c-statistics (corrected for optimism) for developing a PE-related complication within 7, 14 and 30 days were 0.89, 0.88 and 0.87, respectively. There was limited overfitting, as indicated by a shrinkage factor of 0.91.

Conclusions: We propose a simple clinical prediction model with good discriminative performance to predict PE-related complications. Determination of its usefulness in clinical practice awaits further investigation and external validation. © 2020 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

Keywords: PlGF; pre-eclampsia; prediction model; sFlt-1.

Publication types

  • Multicenter Study
  • Observational Study
  • Validation Study

MeSH terms

  • Adult
  • Biomarkers / analysis
  • Female
  • Gestational Age
  • Humans
  • Models, Statistical*
  • Placenta Growth Factor / blood
  • Pre-Eclampsia / blood*
  • Pre-Eclampsia / prevention & control
  • Predictive Value of Tests
  • Pregnancy
  • Pregnancy Complications / diagnosis*
  • Pregnancy Complications / etiology
  • Pregnancy Complications / prevention & control
  • Pregnancy Trimesters / blood
  • Prenatal Diagnosis / methods*
  • Prospective Studies
  • Regression Analysis
  • Reproducibility of Results
  • Risk Assessment
  • Vascular Endothelial Growth Factor Receptor-1 / blood

Substances

  • Biomarkers
  • PGF protein, human
  • Placenta Growth Factor
  • FLT1 protein, human
  • Vascular Endothelial Growth Factor Receptor-1